Home

Myriad Genetics, Inc. - Common Stock (MYGN)

4.4550
+0.0250 (0.56%)
NASDAQ · Last Trade: May 20th, 2:38 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Via StockStory · May 19, 2025
CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · May 19, 2025
3 of Wall Street’s Favorite Stocks in Dangerous Territory
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Via StockStory · May 12, 2025
Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullishstocktwits.com
Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.
Via Stocktwits · May 7, 2025
Earnings Scheduled For May 6, 2025benzinga.com
Via Benzinga · May 6, 2025
Myriad Genetics's Earnings: A Previewbenzinga.com
Via Benzinga · May 5, 2025
What Analysts Are Saying About Myriad Genetics Stockbenzinga.com
Via Benzinga · May 7, 2025
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and EBITDA guidance due to weaker trends in its pharmacogenomics and hereditary cancer testing (women's health) businesses. On the other hand, MYGN significantly beat analysts' EPS and EBITDA expectations. Overall, this was a softer quarter.
Via StockStory · May 7, 2025
Top movers in Wednesday's sessionchartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · May 7, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · May 7, 2025
Crude Oil Falls 1%; Uber Sales Miss Estimatesmarkets/com
Via Benzinga · May 7, 2025
Wednesday's session: top gainers and loserschartmill.com
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · May 7, 2025
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · May 7, 2025
These stocks that are showing activity before the opening bell on Wednesday.chartmill.com
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · May 7, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 7, 2025
Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Via StockStory · May 6, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · May 6, 2025
Which stocks are moving after the closing bell on Tuesday?chartmill.com
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · May 6, 2025
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after the bell. Here’s what to look for.
Via StockStory · May 5, 2025
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via StockStory · May 2, 2025
1 Unprofitable Stock to Target This Week and 2 to Be Wary Of
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via StockStory · May 1, 2025
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 10.9%. This drawdown was worse than the S&P 500’s 5.7% decline.
Via StockStory · April 25, 2025
Demystifying Myriad Genetics: Insights From 10 Analyst Reviewsbenzinga.com
Via Benzinga · April 17, 2025
10 Analysts Assess Myriad Genetics: What You Need To Knowbenzinga.com
Via Benzinga · April 1, 2025
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 1, 2025